en.Wedoany.com Reported - ZEISS Medical Technology announced a strategic agreement with Aier Eye Hospital Group to procure and install 25 ZEISS VISUMAX 800 femtosecond laser devices across multiple Aier hospitals. The signing ceremony was held on June 12, 2026, at the Aier Eye Hospital Group headquarters in Changsha, Hunan Province.
Under the agreement, the 25 ZEISS VISUMAX 800 systems will be gradually deployed across Aier Eye Hospital Group's domestic and international networks starting in the second half of 2026. This strategic collaboration aims to enhance high-quality patient care through technological innovation, providing precise and well-validated refractive surgery to patients worldwide.
Martin Fischer, President and CEO of ZEISS Greater China, stated that Aier Eye Hospital is one of ZEISS Medical Technology's most important global strategic partners, and the two sides will explore deeper collaborative innovation in areas such as international expansion, integrated digital workflows and platforms, and artificial intelligence-assisted diagnostics.
Li Li, Co-founder and Global President of Aier Eye Hospital Group, said the partnership has transcended mere equipment procurement, with both parties jointly exploring comprehensive synergies from clinical management to digital applications. The introduction of 25 ZEISS VISUMAX 800 systems will help Aier further improve surgical efficiency and patient satisfaction, aiming to set a new quality benchmark for global refractive surgery.
At the signing ceremony, ZEISS Medical Technology awarded Aier Eye Hospital Group a "Top Three" honorary plaque, recognizing Aier's global leadership in three dimensions: equipment scale, talent pool, and clinical practice, further deepening their strategic cooperation. These three dimensions include: Aier Eye Hospital will become the ophthalmic institution with the largest installed base of ZEISS VISUMAX 800 systems globally; Aier Eye Hospital has the highest number of ZEISS SMILE pro certified physicians worldwide, highlighting its advantages in technical training and talent development; and Aier Eye Hospital ranks first in China for the total number of KLEx surgeries performed using ZEISS SMILE pro, maintaining a solid position in clinical experience and patient satisfaction.
Not all products, services, or offers are approved or available in every market, and approved labeling and instructions may vary by country. Product specifications may change in design and scope of delivery due to ongoing technical development. Statements by medical professionals reflect only their personal views and experiences and do not necessarily represent the opinions of their affiliated institutions. Medical professionals are solely responsible for the content of their reported experiences and any potential infringements. Carl Zeiss Meditec AG and its affiliates have no clinical evidence supporting the views and statements of medical professionals and assume no responsibility or liability for the content provided by medical professionals. Medical professionals have contractual or other financial relationships with Carl Zeiss Meditec AG and its affiliates and have received financial support.
Carl Zeiss Meditec AG (ISIN: DE0005313704), listed on the TecDAX and SDAX of the German Stock Exchange, is one of the world's leading medical technology companies. The company offers innovative technologies and application-oriented solutions designed to help physicians improve patients' quality of life. It provides complete solutions, including implants and consumables, for diagnosing and treating eye diseases, and creates innovative visualization solutions in the field of microsurgery. The Group employs 5,784 people worldwide and generated revenue of €2.228 billion in the 2024/25 fiscal year (ending September 30).
The Group is headquartered in Jena, Germany, with subsidiaries in Germany and abroad; more than 50% of employees are located in the United States, Japan, Spain, and France. The Center for Application and Research in India (CARIn) in Bangalore and the Carl Zeiss R&D Innovation Center in Shanghai, China, strengthen the company's presence in these rapidly growing economies. Approximately 39% of Carl Zeiss Meditec AG shares are in free float. About 59% are held by Carl Zeiss AG, one of the leading global groups in the optics and optoelectronics industry.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
